<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">transmed</journal-id><journal-title-group><journal-title xml:lang="ru">Трансляционная медицина</journal-title><trans-title-group xml:lang="en"><trans-title>Translational Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2311-4495</issn><issn pub-type="epub">2410-5155</issn><publisher><publisher-name>Almazov National Medical Research Centre, Saint Petersburg, Russia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/2311-4495-2022-9-4-41-61</article-id><article-id custom-type="elpub" pub-id-type="custom">transmed-735</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ТКАНЕВЫЕ, КЛЕТОЧНЫЕ, ГЕНОМНЫЕ И ПРОТЕОМНЫЕ ТЕХНОЛОГИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CELL, TISSUE, AND GENE THERAPY</subject></subj-group></article-categories><title-group><article-title>Роль мембранных рецепторов, ассоциированных с G-белком, в патогенезе остеопороза</article-title><trans-title-group xml:lang="en"><trans-title>Role of G protein-associated membrane receptors in the pathogenesis of osteoporosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Домнина</surname><given-names>А. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Domnina</surname><given-names>A. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Домнина Алиса Павловна,  к.б.н., старший научный сотрудник </p><p>Тихорецкий пр., д. 4, Санкт-Петербург, 194064</p></bio><bio xml:lang="en"><p>Alisa P. Domnina,  Ph.D., senior researcher </p><p>Tikhoretsky ave. 4, Saint Petersburg, 194064 </p></bio><email xlink:type="simple">aldomnina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Краснова</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Krasnova</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Краснова Ольга Александровна, старший лаборант-исследователь </p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Olga A. Krasnova, senior laboratory researcher </p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кулакова</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kulakova</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кулакова Карина Александровна, лаборант-исследователь </p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Karina A. Kulakova, research laboratory assistant </p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сопова</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sopova</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сопова Юлия Викторовна, к.б.н., научный сотрудник </p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Yuliya V. Sopova, Ph.D., research assistant </p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карелкин</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Karelkin</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Карелкин Виталий Владимирович, к.м.н., заведующий травматолого-ортопедическим отделением </p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Vitaliy V. Karelkin, M.D., head of the traumatology and orthopedic department </p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лесняк</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Lesnyak</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лесняк Ольга Михайловна, д.м.н., профессор, кафедра семейной медицины </p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Olga M. Lesnyak, M.D., Professor, Department of Family Medicine </p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Неганова</surname><given-names>И. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Neganova</surname><given-names>I. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Неганова Ирина Эриковна, к.б.н., ведущий научный сотрудник </p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Irina E. Neganova, Ph.D., Leading Researcher </p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение науки «Институт цитологии Российской академии наук»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Cytology of the Russian Academy of Science</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение «Российский ордена Трудового Красного Знамени научно-исследовательский институт травматологии и ортопедии имени Р. Р. Вредена» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Vreden Russian research Institute of traumatology and orthopedics</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Северо-Западный государственный медицинский университет имени И. И. Мечникова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>North-Western State Medical University named after I. I. Mechnikov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>25</day><month>11</month><year>2022</year></pub-date><volume>9</volume><issue>4</issue><fpage>41</fpage><lpage>61</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Домнина А.П., Краснова О.А., Кулакова К.А., Сопова Ю.В., Карелкин В.В., Лесняк О.М., Неганова И.Э., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Домнина А.П., Краснова О.А., Кулакова К.А., Сопова Ю.В., Карелкин В.В., Лесняк О.М., Неганова И.Э.</copyright-holder><copyright-holder xml:lang="en">Domnina A.P., Krasnova O.A., Kulakova K.A., Sopova Y.V., Karelkin V.V., Lesnyak O.M., Neganova I.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://transmed.almazovcentre.ru/jour/article/view/735">https://transmed.almazovcentre.ru/jour/article/view/735</self-uri><abstract><p>Остеопороз — это хроническое заболевание, характеризующееся патологическим изменением костной ткани, чрезмерной хрупкостью и снижением прочности костей в результате преобладания процессов костной резорбции над процессом костеобразования. Данное заболевание проявляется в виде низкотравматических переломов, возникающих при падении с высоты своего роста или при незначительной физической нагрузке. Одним из осложнений остеопороза является перелом шейки бедренной кости, который приводит к высокой летальности, инвалидизации и большим затратам на лечение. Социальная значимость остеопороза определяется его последствиями — переломами тел позвонков и костей периферического скелета, обусловливающими высокий уровень нетрудоспособности, включая инвалидность и смертность. Важно отметить, что у женщин на фоне прекращения менструального цикла развивается постменопаузальный остеопороз. В данном обзоре рассматривается роль мембранных рецепторов, ассоциированных с G-белком (семейство GPCR), в патогенезе данного заболевания и перспективы поиска мишеней среди этих рецепторов для диагностики и лечения остеопороза. Было показано, что изменения генов, кодирующих GPCR, приводят к нарушению ремоделирования костной ткани. Одной из актуальных задач исследования функций белков семейства GPCR является поиск маркеров предрасположенности к дисфункции костной ткани для оптимизации ранней диагностики остеопороза. Исследования на модели остеобластов, дифференцированных из индуцированных плюрипотентных стволовых клеток человека (ИПСКч), полученных от пациентов с остеопорозом, ассоциированным с мутациями в генах семейства GPCR, позволят глубже понять молекулярную природу остеопороза и выявить новые таргетные молекулы для разработки эффективных методов лечения.</p></abstract><trans-abstract xml:lang="en"><p>Osteoporosis is a chronic disease characterized by a pathological change in bone tissue, excessive fragility and a decrease in bone strength as a result of the predominance of bone resorption processes over the process of bone formation. This disease manifests in the form of low-traumatic fractures occurring in result of falling from a height of one’s height, or with little physical exertion. Osteoporosis could result in the fractures of the vertebral bodies and bones of the peripheral skeleton, causing a high level of disability. Of note, postmenopausal osteoporosis develops in women against the background of the cessation of the menstrual cycle. Here we overview the role of G-protein-associated membrane receptors (GPCR family) in the pathogenesis of this disease and the prospects for finding targets among these receptors for the diagnosis and treatment of osteoporosis. Malformations in the genes encoding GPCR lead to impaired bone tissue remodeling. Exploring the functions of GPCR family members is critical to the search for predisposition markers of bone tissue dysfunction and could improve the early diagnosis of osteoporosis. Studies on a model of osteoblasts differentiated from hIPSCs obtained from patients with osteoporosis associated with mutations in the genes of the GPCR family will allow a deeper understanding of the molecular nature of osteoporosis and the identification of new targets for osteoporosis treatment.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>мембранные рецепторы</kwd><kwd>ассоциированные с G-белком</kwd><kwd>мутации</kwd><kwd>нуклеотидный полиморфизм</kwd><kwd>остеопороз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>membrane receptors associated with G-proteins</kwd><kwd>mutations</kwd><kwd>nucleotide polymorphism</kwd><kwd>osteoporosis</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено при финансовой поддержке гранта Министерства науки и высшего образования Российской Федерации (Соглашение №075-15-2021-1075 от 28.09.2021).</funding-statement><funding-statement xml:lang="en">The research was carried out with the financial support of a grant from the Ministry of Science and Higher Education of the Russian Federation (Agreement No. 075-15-2021-1075 dated 09/28/2021).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Siris ES, Adler R, Bilezikian J et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int. 2014; 25(5):1439-1443. DOI: 10.1007/s00198-014-2655-z.</mixed-citation><mixed-citation xml:lang="en">Siris ES, Adler R, Bilezikian J et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int. 2014; 25(5):1439-1443. DOI: 10.1007/s00198-014-2655-z.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Siris ES, Boonen S, Mitchell PJ et al. What’s in a name? What constitutes the clinical diagnosis of osteoporosis? Osteoporos Int. 2012; 23(8):2093-2097. DOI: 10.1007/s00198-012-1991-0.</mixed-citation><mixed-citation xml:lang="en">Siris ES, Boonen S, Mitchell PJ et al. What’s in a name? What constitutes the clinical diagnosis of osteoporosis? Osteoporos Int. 2012; 23(8):2093-2097. DOI: 10.1007/s00198-012-1991-0.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Belaya ZE, Belova KYu, Biryukova EV, et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021; 24(2):4-47. In Russian [ Белая Ж.Е., Белова К.Ю., Бирюкова Е.В., и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Остеопороз и остеопатии. 2021;24(2):4- 47]. DOI: 10.14341/osteo12930</mixed-citation><mixed-citation xml:lang="en">Belaya ZE, Belova KYu, Biryukova EV, et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021; 24(2):4-47. In Russian [ Белая Ж.Е., Белова К.Ю., Бирюкова Е.В., и др. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Остеопороз и остеопатии. 2021;24(2):4- 47]. DOI: 10.14341/osteo12930</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Camacho PM, Petak SM, Binkley N, et al. American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis — 2016. Endocr Pract. 2016; 22(Suppl 4):1- 42. DOI: 10.4158/EP161435.GL.</mixed-citation><mixed-citation xml:lang="en">Camacho PM, Petak SM, Binkley N, et al. American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis — 2016. Endocr Pract. 2016; 22(Suppl 4):1- 42. DOI: 10.4158/EP161435.GL.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kanis JA, Cooper C, Rizzoli R, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019; 30(1):3- 44. DOI: 10.1007/s00198-018-4704-5.</mixed-citation><mixed-citation xml:lang="en">Kanis JA, Cooper C, Rizzoli R, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019; 30(1):3- 44. DOI: 10.1007/s00198-018-4704-5.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Willers C, Norton N, Harvey NC et al. Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteoporos. 2022;17(1):23. DOI: 10.1007/s11657-021-00969-8.</mixed-citation><mixed-citation xml:lang="en">Willers C, Norton N, Harvey NC et al. Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteoporos. 2022;17(1):23. DOI: 10.1007/s11657-021-00969-8.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kanis JA, Norton N, Harvey NC et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos. 2021; 16(1):82. DOI: 10.1007/s11657-020-00871-9.</mixed-citation><mixed-citation xml:lang="en">Kanis JA, Norton N, Harvey NC et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos. 2021; 16(1):82. DOI: 10.1007/s11657-020-00871-9.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lesnyak O.M. International research projects in the osteoporosis: common efforts, one goal. Russian Family Doctor. 2016; 20(2):43-46. In Russian [Лесняк О.М. Международные научные проекты в области остеопороза: общие усилия, одна цель. Российский семейный врач. 2016; 20(2):43-46]. DOI: 10.17816/RFD2016243-46</mixed-citation><mixed-citation xml:lang="en">Lesnyak O.M. International research projects in the osteoporosis: common efforts, one goal. Russian Family Doctor. 2016; 20(2):43-46. In Russian [Лесняк О.М. Международные научные проекты в области остеопороза: общие усилия, одна цель. Российский семейный врач. 2016; 20(2):43-46]. DOI: 10.17816/RFD2016243-46</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Maeda K, Takahashi N, Kobayashi Y. Roles of Wnt signals in bone resorption during physiological and pathological states. J Mol Med (Berl). 2013; 91(1):15-23. DOI: 10.1007/s00109-012-0974-0.</mixed-citation><mixed-citation xml:lang="en">Maeda K, Takahashi N, Kobayashi Y. Roles of Wnt signals in bone resorption during physiological and pathological states. J Mol Med (Berl). 2013; 91(1):15-23. DOI: 10.1007/s00109-012-0974-0.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Boyce BF, Xing L. The RANKL/RANK/OPG pathway. Curr Osteoporos Rep. 2007;5(3):98-104. DOI: 10.1007/s11914-007-0024-y.</mixed-citation><mixed-citation xml:lang="en">Boyce BF, Xing L. The RANKL/RANK/OPG pathway. Curr Osteoporos Rep. 2007;5(3):98-104. DOI: 10.1007/s11914-007-0024-y.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Chen X, Wang Z, Duan N et al. Osteoblastosteoclast interactions. Connect Tissue Res. 2018; 59(2):99- 107. DOI: 10.1080/03008207.2017.1290085.</mixed-citation><mixed-citation xml:lang="en">Chen X, Wang Z, Duan N et al. Osteoblastosteoclast interactions. Connect Tissue Res. 2018; 59(2):99- 107. DOI: 10.1080/03008207.2017.1290085.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang YY, Liu PY, Lu Y et al. Tests of linkage and association of PTH/PTHrP receptor type 1 gene with bone mineral density and height in Caucasians. J Bone Miner Metab. 2006; 24(1):36-41. DOI: 10.1007/s00774-005-0643-2.</mixed-citation><mixed-citation xml:lang="en">Zhang YY, Liu PY, Lu Y et al. Tests of linkage and association of PTH/PTHrP receptor type 1 gene with bone mineral density and height in Caucasians. J Bone Miner Metab. 2006; 24(1):36-41. DOI: 10.1007/s00774-005-0643-2.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lee SH, Kim TS, Choi Y et al. Osteoimmunology: cytokines and the skeletal system. BMB Rep. 2008; 41(7):495-510. DOI: 10.5483/bmbrep.2008.41.7.495</mixed-citation><mixed-citation xml:lang="en">Lee SH, Kim TS, Choi Y et al. Osteoimmunology: cytokines and the skeletal system. BMB Rep. 2008; 41(7):495-510. DOI: 10.5483/bmbrep.2008.41.7.495</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Gao Y, Grassi F, Ryan MR et al. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest. 2007; 117(1):122-132. DOI: 10.1172/JCI30074</mixed-citation><mixed-citation xml:lang="en">Gao Y, Grassi F, Ryan MR et al. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest. 2007; 117(1):122-132. DOI: 10.1172/JCI30074</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lencel P, Magne D. Inflammaging: the driving force in osteoporosis? Med Hypotheses. 2011; 76(3):317- 321. DOI: 10.1016/j.mehy.2010.09.023</mixed-citation><mixed-citation xml:lang="en">Lencel P, Magne D. Inflammaging: the driving force in osteoporosis? Med Hypotheses. 2011; 76(3):317- 321. DOI: 10.1016/j.mehy.2010.09.023</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bondeson J, Blom AB, Wainwright S et al. The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum. 2010; 62(3):647-657. DOI: 10.1002/art.27290.</mixed-citation><mixed-citation xml:lang="en">Bondeson J, Blom AB, Wainwright S et al. The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum. 2010; 62(3):647-657. DOI: 10.1002/art.27290.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Pino AM, Ríos S, Astudillo P et al. Concentration of adipogenic and proinflammatory cytokines in the bone marrow supernatant fluid of osteoporotic women. J Bone Miner Res. 2010; 25(3):492-498. DOI: 10.1359/jbmr.090802</mixed-citation><mixed-citation xml:lang="en">Pino AM, Ríos S, Astudillo P et al. Concentration of adipogenic and proinflammatory cytokines in the bone marrow supernatant fluid of osteoporotic women. J Bone Miner Res. 2010; 25(3):492-498. DOI: 10.1359/jbmr.090802</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Pacifici R, Brown C, Puscheck E et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci U S A. 1991; 88(12):5134-5138. DOI: 10.1073/pnas.88.12.5134</mixed-citation><mixed-citation xml:lang="en">Pacifici R, Brown C, Puscheck E et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci U S A. 1991; 88(12):5134-5138. DOI: 10.1073/pnas.88.12.5134</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Pfeilschifter J, Köditz R, Pfohl M et al. Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002; 23(1):90-119. DOI: 10.1210/edrv.23.1.0456</mixed-citation><mixed-citation xml:lang="en">Pfeilschifter J, Köditz R, Pfohl M et al. Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002; 23(1):90-119. DOI: 10.1210/edrv.23.1.0456</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest. 2006; 116(5):1186-1194. DOI: 10.1172/JCI28550.</mixed-citation><mixed-citation xml:lang="en">Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest. 2006; 116(5):1186-1194. DOI: 10.1172/JCI28550.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Cauley JA, Danielson ME, Boudreau RM et al. Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res. 2007; 22(7):1088-1095. DOI: 10.1359/jbmr.070409</mixed-citation><mixed-citation xml:lang="en">Cauley JA, Danielson ME, Boudreau RM et al. Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res. 2007; 22(7):1088-1095. DOI: 10.1359/jbmr.070409</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Charatcharoenwitthaya N, Khosla S, Atkinson EJ et al. Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res. 2007; 22(5):724-729. DOI: 10.1359/jbmr.070207.</mixed-citation><mixed-citation xml:lang="en">Charatcharoenwitthaya N, Khosla S, Atkinson EJ et al. Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res. 2007; 22(5):724-729. DOI: 10.1359/jbmr.070207.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Takayanagi H, Kim S, Matsuo K et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 2002; 416(6882):744- 749. DOI: 10.1038/416744a.</mixed-citation><mixed-citation xml:lang="en">Takayanagi H, Kim S, Matsuo K et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 2002; 416(6882):744- 749. DOI: 10.1038/416744a.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Takayanagi H, Ogasawara K, Hida S et al. T-cellmediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature. 2000; 408(6812):600-605. DOI: 10.1038/35046102</mixed-citation><mixed-citation xml:lang="en">Takayanagi H, Ogasawara K, Hida S et al. T-cellmediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature. 2000; 408(6812):600-605. DOI: 10.1038/35046102</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Cenci S, Toraldo G, Weitzmann MN et al. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci U S A. 2003; 100(18):10405-10410. DOI: 10.1073/pnas.1533207100.</mixed-citation><mixed-citation xml:lang="en">Cenci S, Toraldo G, Weitzmann MN et al. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci U S A. 2003; 100(18):10405-10410. DOI: 10.1073/pnas.1533207100.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Janssens K, ten Dijke P, Janssens S et al. Transforming growth factor-beta1 to the bone. Endocr Rev. 2005; 26(6):743-774. DOI: 10.1210/er.2004-0001</mixed-citation><mixed-citation xml:lang="en">Janssens K, ten Dijke P, Janssens S et al. Transforming growth factor-beta1 to the bone. Endocr Rev. 2005; 26(6):743-774. DOI: 10.1210/er.2004-0001</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kudo O, Fujikawa Y, Itonaga I et al. Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. J Pathol. 2002; 198(2):220- 227. DOI: 10.1002/path.1190</mixed-citation><mixed-citation xml:lang="en">Kudo O, Fujikawa Y, Itonaga I et al. Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. J Pathol. 2002; 198(2):220- 227. DOI: 10.1002/path.1190</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Kudo O, Sabokbar A, Pocock A et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003; 32(1):1-7. DOI: 10.1016/s8756-3282(02)00915-8</mixed-citation><mixed-citation xml:lang="en">Kudo O, Sabokbar A, Pocock A et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003; 32(1):1-7. DOI: 10.1016/s8756-3282(02)00915-8</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Yoshitake F, Itoh S, Narita H, et al. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J Biol Chem. 2008; 283(17):11535-11540. DOI: 10.1074/jbc.M607999200</mixed-citation><mixed-citation xml:lang="en">Yoshitake F, Itoh S, Narita H, et al. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J Biol Chem. 2008; 283(17):11535-11540. DOI: 10.1074/jbc.M607999200</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Theoleyre S, Wittrant Y, Tat SK, et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004; 15(6):457-475. DOI: 10.1016/j.cytogfr.2004.06.004</mixed-citation><mixed-citation xml:lang="en">Theoleyre S, Wittrant Y, Tat SK, et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004; 15(6):457-475. DOI: 10.1016/j.cytogfr.2004.06.004</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Fuller K, Murphy C, Kirstein B, et al. TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology. 2002; 143(3):1108-1118. DOI: 10.1210/endo.143.3.8701</mixed-citation><mixed-citation xml:lang="en">Fuller K, Murphy C, Kirstein B, et al. TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology. 2002; 143(3):1108-1118. DOI: 10.1210/endo.143.3.8701</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Itonaga I, Sabokbar A, Sun SG, et al. Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. Bone. 2004; 34(1):57-64. DOI: 10.1016/j.bone.2003.08.008.</mixed-citation><mixed-citation xml:lang="en">Itonaga I, Sabokbar A, Sun SG, et al. Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. Bone. 2004; 34(1):57-64. DOI: 10.1016/j.bone.2003.08.008.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 2000; 191(2):275-286. DOI: 10.1084/jem.191.2.275</mixed-citation><mixed-citation xml:lang="en">Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 2000; 191(2):275-286. DOI: 10.1084/jem.191.2.275</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Baim S, Binkley N, Bilezikian JP, et al. Official positions of the international society for clinical densitometry and executive summary of the 2007 ISCD position development conference. J Clin Densitom. 2008; 11(1):75-91. DOI: 10.1016/j.jocd.2007.12.007.</mixed-citation><mixed-citation xml:lang="en">Baim S, Binkley N, Bilezikian JP, et al. Official positions of the international society for clinical densitometry and executive summary of the 2007 ISCD position development conference. J Clin Densitom. 2008; 11(1):75-91. DOI: 10.1016/j.jocd.2007.12.007.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Watts NB, Leslie WD, Foldes AJ, et al. International society for clinical densitometry position development conference: task force on normative databases. J Clin Densitom. 2013; 16(4):472-481. DOI: 10.1016/j.jocd.2013.08.001</mixed-citation><mixed-citation xml:lang="en">Watts NB, Leslie WD, Foldes AJ, et al. International society for clinical densitometry position development conference: task force on normative databases. J Clin Densitom. 2013; 16(4):472-481. DOI: 10.1016/j.jocd.2013.08.001</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Lesniak OM. Osteoporosis audit in the Russian Federation. Profilakticheskaya Meditsina. 2011; 14(2):7- 10. In Russian [Лесняк О.М. Аудит состояния проблемы остеопороза в Российской Федерации. Профилактическая медицина. 2011;14(2):7-10].</mixed-citation><mixed-citation xml:lang="en">Lesniak OM. Osteoporosis audit in the Russian Federation. Profilakticheskaya Meditsina. 2011; 14(2):7- 10. In Russian [Лесняк О.М. Аудит состояния проблемы остеопороза в Российской Федерации. Профилактическая медицина. 2011;14(2):7-10].</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Nikitinskaya OA, Toroptsova NV. Assessment of 10-year probability of osteoporotic fractures with the russian model of FRAX® in a population-based sample 5 regions of Russia. Meditsinskiy sovet=Medical Council. 2017; (1S):103- 107. In Russian [Никитинская О.А., Торопцова Н.В. Оценка 10-летней вероятности остеопоротических переломов с помощью российской модели FRAX® в популяционных выборках 5 регионов России. Медицинский совет. 2017; (1S):103-107]. DOI: 10.21518/2079-701X-2017-0-103-107</mixed-citation><mixed-citation xml:lang="en">Nikitinskaya OA, Toroptsova NV. Assessment of 10-year probability of osteoporotic fractures with the russian model of FRAX® in a population-based sample 5 regions of Russia. Meditsinskiy sovet=Medical Council. 2017; (1S):103- 107. In Russian [Никитинская О.А., Торопцова Н.В. Оценка 10-летней вероятности остеопоротических переломов с помощью российской модели FRAX® в популяционных выборках 5 регионов России. Медицинский совет. 2017; (1S):103-107]. DOI: 10.21518/2079-701X-2017-0-103-107</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Tu KN, Lie JD, Wan CKV, et al. Osteoporosis: A Review of Treatment Options. P T. 2018; 43(2):92-104.</mixed-citation><mixed-citation xml:lang="en">Tu KN, Lie JD, Wan CKV, et al. Osteoporosis: A Review of Treatment Options. P T. 2018; 43(2):92-104.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Nancollas GH, Tang R., Gulde S. et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006; 38(5):617– 627. DOI: 10.1016/j.bone.2005.05.003</mixed-citation><mixed-citation xml:lang="en">Nancollas GH, Tang R., Gulde S. et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006; 38(5):617– 627. DOI: 10.1016/j.bone.2005.05.003</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003; 9(32):2643-2658. DOI: 10.2174/1381612033453640.</mixed-citation><mixed-citation xml:lang="en">Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003; 9(32):2643-2658. DOI: 10.2174/1381612033453640.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Wu FY, Liu CS, Liao LN et al. Vitamin D receptor variability and physical activity are jointly associated with low handgrip strength and osteoporosis in communitydwelling elderly people in Taiwan: the Taichung Community Health Study for Elders (TCHS-E). Osteoporos Int. 2014; 25(7):1917-1929. DOI: 10.1007/s00198-014-2691-8.</mixed-citation><mixed-citation xml:lang="en">Wu FY, Liu CS, Liao LN et al. Vitamin D receptor variability and physical activity are jointly associated with low handgrip strength and osteoporosis in communitydwelling elderly people in Taiwan: the Taichung Community Health Study for Elders (TCHS-E). Osteoporos Int. 2014; 25(7):1917-1929. DOI: 10.1007/s00198-014-2691-8.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Luo L, Xia W, Nie M et al. Association of ESR1 and C6orf97 gene polymorphism with osteoporosis in postmenopausal women. Mol Biol Rep. 2014; 41(5):3235- 3243. DOI: 10.1007/s11033-014-3186-6.</mixed-citation><mixed-citation xml:lang="en">Luo L, Xia W, Nie M et al. Association of ESR1 and C6orf97 gene polymorphism with osteoporosis in postmenopausal women. Mol Biol Rep. 2014; 41(5):3235- 3243. DOI: 10.1007/s11033-014-3186-6.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Tural S, Alayli G, Kara N et al. Association between osteoporosis and polymorphisms of the IL-10 and TGF-beta genes in Turkish postmenopausal women. Hum Immunol. 2013; 74(9):1179-1183. DOI: 10.1016/j.humimm.2013.03.005.</mixed-citation><mixed-citation xml:lang="en">Tural S, Alayli G, Kara N et al. Association between osteoporosis and polymorphisms of the IL-10 and TGF-beta genes in Turkish postmenopausal women. Hum Immunol. 2013; 74(9):1179-1183. DOI: 10.1016/j.humimm.2013.03.005.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Tural S, Kara N, Alayli G et al. Association between osteoporosis and polymorphisms of the bone Gla protein, estrogen receptor 1, collagen 1-A1 and calcitonin receptor genes in Turkish postmenopausal women. Gene. 2013; 515(1):167-172. DOI: 10.1016/j.gene.2012.10.041</mixed-citation><mixed-citation xml:lang="en">Tural S, Kara N, Alayli G et al. Association between osteoporosis and polymorphisms of the bone Gla protein, estrogen receptor 1, collagen 1-A1 and calcitonin receptor genes in Turkish postmenopausal women. Gene. 2013; 515(1):167-172. DOI: 10.1016/j.gene.2012.10.041</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Schöneberg T, Schulz A, Biebermann H et al. Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol Ther. 2004; 104(3):173-206. DOI: 10.1016/j.pharmthera.2004.08.008.</mixed-citation><mixed-citation xml:lang="en">Schöneberg T, Schulz A, Biebermann H et al. Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol Ther. 2004; 104(3):173-206. DOI: 10.1016/j.pharmthera.2004.08.008.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Luo J, Sun P, Siwko S et al. The role of GPCRs in bone diseases and dysfunctions. Bone Res. 2019; 7:19. DOI: 10.1038/s41413-019-0059-6.</mixed-citation><mixed-citation xml:lang="en">Luo J, Sun P, Siwko S et al. The role of GPCRs in bone diseases and dysfunctions. Bone Res. 2019; 7:19. DOI: 10.1038/s41413-019-0059-6.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Schöneberg T, Liebscher I. Mutations in G Protein-Coupled Receptors: Mechanisms, Pathophysiology and Potential Therapeutic Approaches. Pharmacol Rev. 2021; 73(1):89-119. DOI: 10.1124/pharmrev.120.000011</mixed-citation><mixed-citation xml:lang="en">Schöneberg T, Liebscher I. Mutations in G Protein-Coupled Receptors: Mechanisms, Pathophysiology and Potential Therapeutic Approaches. Pharmacol Rev. 2021; 73(1):89-119. DOI: 10.1124/pharmrev.120.000011</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Stoy H, Gurevich VV. How genetic errors in GPCRs affect their function: Possible therapeutic strategies. Genes Dis. 2015; 2(2):108-132. DOI: 10.1016/j.gendis.2015.02.005</mixed-citation><mixed-citation xml:lang="en">Stoy H, Gurevich VV. How genetic errors in GPCRs affect their function: Possible therapeutic strategies. Genes Dis. 2015; 2(2):108-132. DOI: 10.1016/j.gendis.2015.02.005</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Q, Iverson TM, Gurevich VV. Structural Basis of Arrestin-Dependent Signal Transduction. Trends Biochem Sci. 2018; 43(6):412-423. DOI: 10.1016/j.tibs.2018.03.005.</mixed-citation><mixed-citation xml:lang="en">Chen Q, Iverson TM, Gurevich VV. Structural Basis of Arrestin-Dependent Signal Transduction. Trends Biochem Sci. 2018; 43(6):412-423. DOI: 10.1016/j.tibs.2018.03.005.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Schöneberg J, Lee IH, Iwasa JH et al. Reversetopology membrane scission by the ESCRT proteins. Nat Rev Mol Cell Biol. 2017; 18(1):5-17. DOI: 10.1038/nrm.2016.121.</mixed-citation><mixed-citation xml:lang="en">Schöneberg J, Lee IH, Iwasa JH et al. Reversetopology membrane scission by the ESCRT proteins. Nat Rev Mol Cell Biol. 2017; 18(1):5-17. DOI: 10.1038/nrm.2016.121.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Dvorak MM, Siddiqua A, Ward DT, et al. Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of calciotropic hormones. Proc Natl Acad Sci USA. 2004; 101(14):5140–5145. DOI: 10.1073/pnas.0306141101</mixed-citation><mixed-citation xml:lang="en">Dvorak MM, Siddiqua A, Ward DT, et al. Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of calciotropic hormones. Proc Natl Acad Sci USA. 2004; 101(14):5140–5145. DOI: 10.1073/pnas.0306141101</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Yano S, Sugimoto T, Tsukamoto T, et al. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int. 2000;58(5):1980-1986. DOI: 10.1111/j.1523-1755.2000.00370.x.</mixed-citation><mixed-citation xml:lang="en">Yano S, Sugimoto T, Tsukamoto T, et al. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int. 2000;58(5):1980-1986. DOI: 10.1111/j.1523-1755.2000.00370.x.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Takeyama S, Yoshimura Y, Shirai Y, et al. Low calcium environment effects osteoprotegerin ligand/ osteoclast differentiation factor. Biochem Biophys Res Commun. 2000; 276(2):524–529. DOI: 10.1006/bbrc.2000.3498</mixed-citation><mixed-citation xml:lang="en">Takeyama S, Yoshimura Y, Shirai Y, et al. Low calcium environment effects osteoprotegerin ligand/ osteoclast differentiation factor. Biochem Biophys Res Commun. 2000; 276(2):524–529. DOI: 10.1006/bbrc.2000.3498</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Välimäki S, Farnebo F, Forsberg L et al. Heterogeneous expression of receptor mRNAs in parathyroid glands of secondary hyperparathyroidism. Kidney Int. 2001; 60(5):1666-1675. DOI: 10.1046/j.1523-1755.2001.00986.x.</mixed-citation><mixed-citation xml:lang="en">Välimäki S, Farnebo F, Forsberg L et al. Heterogeneous expression of receptor mRNAs in parathyroid glands of secondary hyperparathyroidism. Kidney Int. 2001; 60(5):1666-1675. DOI: 10.1046/j.1523-1755.2001.00986.x.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Cheshmedzhieva D, Ilieva S, Permyakov EA et al. Ca2+/Sr2+ selectivity in calcium-sensing receptor (CaSR): implications for strontium’s anti-osteoporosis effect. Biomolecules. 2021; 11(11):1576. DOI: 10.3390/biom11111576</mixed-citation><mixed-citation xml:lang="en">Cheshmedzhieva D, Ilieva S, Permyakov EA et al. Ca2+/Sr2+ selectivity in calcium-sensing receptor (CaSR): implications for strontium’s anti-osteoporosis effect. Biomolecules. 2021; 11(11):1576. DOI: 10.3390/biom11111576</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Chang W, Tu C, Chen TH et al. The extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal development. Sci Signal. 2008; 1(35):ra1. DOI: 10.1126/scisignal.1159945.</mixed-citation><mixed-citation xml:lang="en">Chang W, Tu C, Chen TH et al. The extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal development. Sci Signal. 2008; 1(35):ra1. DOI: 10.1126/scisignal.1159945.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Hendy GN, Guarnieri V, Canaff L. Calciumsensing receptor and associated diseases. Prog Mol Biol Transl Sci. 2009; 89:31-95. DOI: 10.1016/S1877-1173(09)89003-0.</mixed-citation><mixed-citation xml:lang="en">Hendy GN, Guarnieri V, Canaff L. Calciumsensing receptor and associated diseases. Prog Mol Biol Transl Sci. 2009; 89:31-95. DOI: 10.1016/S1877-1173(09)89003-0.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Menko FH, Bijvoet OL, Fronen JL, et al. Familial benign hypercalcaemia. Study of a large family. Q J Med. 1983; 52(206):120-140.</mixed-citation><mixed-citation xml:lang="en">Menko FH, Bijvoet OL, Fronen JL, et al. Familial benign hypercalcaemia. Study of a large family. Q J Med. 1983; 52(206):120-140.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Fitzpatrick LA, Dabrowski CE, Cicconetti G, et al. Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res. 2012; 27(2):255-262. DOI: 10.1002/jbmr.554</mixed-citation><mixed-citation xml:lang="en">Fitzpatrick LA, Dabrowski CE, Cicconetti G, et al. Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res. 2012; 27(2):255-262. DOI: 10.1002/jbmr.554</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Halse J, Greenspan S, Cosman F, et al. A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2014; 99(11):E2207-2215. DOI: 10.1210/jc.2013-4009</mixed-citation><mixed-citation xml:lang="en">Halse J, Greenspan S, Cosman F, et al. A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2014; 99(11):E2207-2215. DOI: 10.1210/jc.2013-4009</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Goltzman D, Hendy GN. The calcium-sensing receptor in bone--mechanistic and therapeutic insights. Nat Rev Endocrinol. 2015; 11(5):298-307. DOI: 10.1038/nrendo.2015.30</mixed-citation><mixed-citation xml:lang="en">Goltzman D, Hendy GN. The calcium-sensing receptor in bone--mechanistic and therapeutic insights. Nat Rev Endocrinol. 2015; 11(5):298-307. DOI: 10.1038/nrendo.2015.30</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Di Nisio A, Rocca MS, Ghezzi M et al. Calciumsensing receptor polymorphisms increase the risk of osteoporosis in ageing males. Endocrine. 2018; 61(2):349- 352. DOI: 10.1007/s12020-017-1429-8.</mixed-citation><mixed-citation xml:lang="en">Di Nisio A, Rocca MS, Ghezzi M et al. Calciumsensing receptor polymorphisms increase the risk of osteoporosis in ageing males. Endocrine. 2018; 61(2):349- 352. DOI: 10.1007/s12020-017-1429-8.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Gat-Yablonski G, Ben-Ari T, Shtaif B et al. Leptin reverses the inhibitory effect of caloric restriction on longitudinal growth. Endocrinology. 2004; 145(1):343-350. DOI: 10.1210/en.2003-0910.</mixed-citation><mixed-citation xml:lang="en">Gat-Yablonski G, Ben-Ari T, Shtaif B et al. Leptin reverses the inhibitory effect of caloric restriction on longitudinal growth. Endocrinology. 2004; 145(1):343-350. DOI: 10.1210/en.2003-0910.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Welt CK, Chan JL, Bullen J et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004; 351(10):987-997. DOI: 10.1056/NEJMoa040388</mixed-citation><mixed-citation xml:lang="en">Welt CK, Chan JL, Bullen J et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004; 351(10):987-997. DOI: 10.1056/NEJMoa040388</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Lee HJ, Kim H, Ku SY et al. Association between polymorphisms in leptin, leptin receptor, and β-adrenergic receptor genes and bone mineral density in postmenopausal Korean women. Menopause. 2014; 21(1):67-73. DOI: 10.1097/GME.0b013e31829366ed</mixed-citation><mixed-citation xml:lang="en">Lee HJ, Kim H, Ku SY et al. Association between polymorphisms in leptin, leptin receptor, and β-adrenergic receptor genes and bone mineral density in postmenopausal Korean women. Menopause. 2014; 21(1):67-73. DOI: 10.1097/GME.0b013e31829366ed</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Akune T, Ohba S, Kamekura S et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004; 113(6):846-855. DOI: 10.1172/JCI19900</mixed-citation><mixed-citation xml:lang="en">Akune T, Ohba S, Kamekura S et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004; 113(6):846-855. DOI: 10.1172/JCI19900</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Quennell JH, Mulligan AC, Tups A et al. Leptin indirectly regulates gonadotropin-releasing hormone neuronal function. Endocrinology. 2009; 150(6):2805-2812. DOI: 10.1210/en.2008-1693</mixed-citation><mixed-citation xml:lang="en">Quennell JH, Mulligan AC, Tups A et al. Leptin indirectly regulates gonadotropin-releasing hormone neuronal function. Endocrinology. 2009; 150(6):2805-2812. DOI: 10.1210/en.2008-1693</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Loram LC, Culp ME, Connolly-Strong EC et al. Melanocortin peptides: potential targets in systemic lupus erythematosus. Inflammation. 2015; 38(1):260-271. DOI: 10.1007/s10753-014-0029-5</mixed-citation><mixed-citation xml:lang="en">Loram LC, Culp ME, Connolly-Strong EC et al. Melanocortin peptides: potential targets in systemic lupus erythematosus. Inflammation. 2015; 38(1):260-271. DOI: 10.1007/s10753-014-0029-5</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Farooqi IS, Yeo GS, Keogh JM et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest. 2000; 106(2):271-279. DOI: 10.1172/JCI9397</mixed-citation><mixed-citation xml:lang="en">Farooqi IS, Yeo GS, Keogh JM et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest. 2000; 106(2):271-279. DOI: 10.1172/JCI9397</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Lin L, Conway GS, Hill NR et al. A homozygous R262Q mutation in the gonadotropin-releasing hormone receptor presenting as constitutional delay of growth and puberty with subsequent borderline oligospermia. J Clin Endocrinol Metab. 2006; 91(12):5117-5121. DOI: 10.1210/jc.2006-0807</mixed-citation><mixed-citation xml:lang="en">Lin L, Conway GS, Hill NR et al. A homozygous R262Q mutation in the gonadotropin-releasing hormone receptor presenting as constitutional delay of growth and puberty with subsequent borderline oligospermia. J Clin Endocrinol Metab. 2006; 91(12):5117-5121. DOI: 10.1210/jc.2006-0807</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Man GC, Wong JH, Wang WW et al. Abnormal melatonin receptor 1B expression in osteoblasts from girls with adolescent idiopathic scoliosis. J Pineal Res. 2011; 50(4):395-402. DOI: 10.1111/j.1600-079X.2011.00857.x</mixed-citation><mixed-citation xml:lang="en">Man GC, Wong JH, Wang WW et al. Abnormal melatonin receptor 1B expression in osteoblasts from girls with adolescent idiopathic scoliosis. J Pineal Res. 2011; 50(4):395-402. DOI: 10.1111/j.1600-079X.2011.00857.x</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y, Zhou J, Wu Y et al. Association of osteoporosis with genetic variants of circadian genes in Chinese geriatrics. Osteoporos Int. 2016; 27(4):1485-1492. DOI: 10.1007/s00198-015-3391-8</mixed-citation><mixed-citation xml:lang="en">Li Y, Zhou J, Wu Y et al. Association of osteoporosis with genetic variants of circadian genes in Chinese geriatrics. Osteoporos Int. 2016; 27(4):1485-1492. DOI: 10.1007/s00198-015-3391-8</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol. 2004; 141(5):765-774. DOI: 10.1038/sj.bjp.0705666.</mixed-citation><mixed-citation xml:lang="en">De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol. 2004; 141(5):765-774. DOI: 10.1038/sj.bjp.0705666.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003; 4(11):873-884. DOI: 10.1038/nrn1247</mixed-citation><mixed-citation xml:lang="en">Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003; 4(11):873-884. DOI: 10.1038/nrn1247</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Idris AI, Ralston SH. Role of cannabinoids in the regulation of bone remodeling. Front Endocrinol (Lausanne). 2012; 3:136. DOI: 10.3389/fendo.2012.00136</mixed-citation><mixed-citation xml:lang="en">Idris AI, Ralston SH. Role of cannabinoids in the regulation of bone remodeling. Front Endocrinol (Lausanne). 2012; 3:136. DOI: 10.3389/fendo.2012.00136</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Bab I, Zimmer A. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol. 2008; 153(2):182- 188. DOI: 10.1038/sj.bjp.0707593</mixed-citation><mixed-citation xml:lang="en">Bab I, Zimmer A. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol. 2008; 153(2):182- 188. DOI: 10.1038/sj.bjp.0707593</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Bab I, Ofek O, Tam J et al. Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol. 2008; 20 Suppl 1:69-74. DOI: 10.1111/j.1365-2826.2008.01675.x</mixed-citation><mixed-citation xml:lang="en">Bab I, Ofek O, Tam J et al. Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol. 2008; 20 Suppl 1:69-74. DOI: 10.1111/j.1365-2826.2008.01675.x</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Idris AI, van ‘t Hof RJ, Greig IR et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med. 2005; 11(7):774-779. DOI: 10.1038/nm1255</mixed-citation><mixed-citation xml:lang="en">Idris AI, van ‘t Hof RJ, Greig IR et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med. 2005; 11(7):774-779. DOI: 10.1038/nm1255</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Sophocleous A, Landao-Bassonga E, Van’t Hof RJ et al. The type 2 cannabinoid receptor regulates bone mass and ovariectomy-induced bone loss by affecting osteoblast differentiation and bone formation. Endocrinology. 2011; 152(6):2141-2149. DOI: 10.1210/en.2010-0930</mixed-citation><mixed-citation xml:lang="en">Sophocleous A, Landao-Bassonga E, Van’t Hof RJ et al. The type 2 cannabinoid receptor regulates bone mass and ovariectomy-induced bone loss by affecting osteoblast differentiation and bone formation. Endocrinology. 2011; 152(6):2141-2149. DOI: 10.1210/en.2010-0930</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Qian H, Zhao Y, Peng Y et al. Activation of cannabinoid receptor CB2 regulates osteogenic and osteoclastogenic gene expression in human periodontal ligament cells. J Periodontal Res. 2010; 45(4):504-511. DOI: 10.1111/j.1600-0765.2009.01265.x</mixed-citation><mixed-citation xml:lang="en">Qian H, Zhao Y, Peng Y et al. Activation of cannabinoid receptor CB2 regulates osteogenic and osteoclastogenic gene expression in human periodontal ligament cells. J Periodontal Res. 2010; 45(4):504-511. DOI: 10.1111/j.1600-0765.2009.01265.x</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Napimoga MH, Benatti BB, Lima FO et al. Cannabidiol decreases bone resorption by inhibiting RANK/ RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats. Int Immunopharmacol. 2009; 9(2):216-222. DOI: 10.1016/j.intimp.2008.11.010</mixed-citation><mixed-citation xml:lang="en">Napimoga MH, Benatti BB, Lima FO et al. Cannabidiol decreases bone resorption by inhibiting RANK/ RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats. Int Immunopharmacol. 2009; 9(2):216-222. DOI: 10.1016/j.intimp.2008.11.010</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Geng DC, Xu YZ, Yang HL et al. Cannabinoid receptor-2 selective antagonist negatively regulates receptor activator of nuclear factor JB ligand mediated osteoclastogenesis. Chin Med J (Engl). 2011; 124(4):586-590.</mixed-citation><mixed-citation xml:lang="en">Geng DC, Xu YZ, Yang HL et al. Cannabinoid receptor-2 selective antagonist negatively regulates receptor activator of nuclear factor JB ligand mediated osteoclastogenesis. Chin Med J (Engl). 2011; 124(4):586-590.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Wang B, Lian K, Li J et al. Restoration of osteogenic differentiation by overexpression of cannabinoid receptor 2 in bone marrow mesenchymal stem cells isolated from osteoporotic patients. Exp Ther Med. 2018; 15(1):357- 364. DOI: 10.3892/etm.2017.5369</mixed-citation><mixed-citation xml:lang="en">Wang B, Lian K, Li J et al. Restoration of osteogenic differentiation by overexpression of cannabinoid receptor 2 in bone marrow mesenchymal stem cells isolated from osteoporotic patients. Exp Ther Med. 2018; 15(1):357- 364. DOI: 10.3892/etm.2017.5369</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Woo JH, Kim H, Kim JH et al. Cannabinoid receptor gene polymorphisms and bone mineral density in Korean postmenopausal women. Menopause. 2015; 22(5):512-519. DOI: 10.1097/GME.0000000000000339</mixed-citation><mixed-citation xml:lang="en">Woo JH, Kim H, Kim JH et al. Cannabinoid receptor gene polymorphisms and bone mineral density in Korean postmenopausal women. Menopause. 2015; 22(5):512-519. DOI: 10.1097/GME.0000000000000339</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Sophocleous A, Marino S, Kabir D et al. Combined deficiency of the Cnr1 and Cnr2 receptors protects against age-related bone loss by osteoclast inhibition. Aging Cell. 2017; 16(5):1051-1061. DOI: 10.1111/acel.12638</mixed-citation><mixed-citation xml:lang="en">Sophocleous A, Marino S, Kabir D et al. Combined deficiency of the Cnr1 and Cnr2 receptors protects against age-related bone loss by osteoclast inhibition. Aging Cell. 2017; 16(5):1051-1061. DOI: 10.1111/acel.12638</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Freemantle N, Holmes J, Hockey A et al. How strong is the association between abdominal obesity and the incidence of type 2 diabetes? Int J Clin Pract. 2008; 62(9):1391-1396. DOI: 10.1111/j.1742-1241.2008.01805.x</mixed-citation><mixed-citation xml:lang="en">Freemantle N, Holmes J, Hockey A et al. How strong is the association between abdominal obesity and the incidence of type 2 diabetes? Int J Clin Pract. 2008; 62(9):1391-1396. DOI: 10.1111/j.1742-1241.2008.01805.x</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Styrkarsdottir U, Thorleifsson G, Sulem P et al. Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits. Nature. 2013; 497(7450):517–520. DOI: 10.1038/nature12124.</mixed-citation><mixed-citation xml:lang="en">Styrkarsdottir U, Thorleifsson G, Sulem P et al. Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits. Nature. 2013; 497(7450):517–520. DOI: 10.1038/nature12124.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Shi SQ, Li SS, Zhang XY et al. LGR4 gene polymorphisms are associated with bone and obesity phenotypes in chinese female nuclear families. Front Endocrinol (Lausanne). 2021; 12:656077. DOI: 10.3389/fendo.2021.656077</mixed-citation><mixed-citation xml:lang="en">Shi SQ, Li SS, Zhang XY et al. LGR4 gene polymorphisms are associated with bone and obesity phenotypes in chinese female nuclear families. Front Endocrinol (Lausanne). 2021; 12:656077. DOI: 10.3389/fendo.2021.656077</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Liu RD, Chen RX, Li WR et al. The Glu727 allele of thyroid stimulating hormone receptor gene is associated with osteoporosis. N Am J Med Sci. 2012; 4(7):300-304. DOI: 10.4103/1947-2714.98588</mixed-citation><mixed-citation xml:lang="en">Liu RD, Chen RX, Li WR et al. The Glu727 allele of thyroid stimulating hormone receptor gene is associated with osteoporosis. N Am J Med Sci. 2012; 4(7):300-304. DOI: 10.4103/1947-2714.98588</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">van der Deure WM, Uitterlinden AG, Hofman A et al. Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on bone: the Rotterdam Study. Clin Endocrinol (Oxf). 2008; 68(2):175-181. DOI: 10.1111/j.1365-2265.2007.03016.x.</mixed-citation><mixed-citation xml:lang="en">van der Deure WM, Uitterlinden AG, Hofman A et al. Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on bone: the Rotterdam Study. Clin Endocrinol (Oxf). 2008; 68(2):175-181. DOI: 10.1111/j.1365-2265.2007.03016.x.</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Rendina D, Gianfrancesco F, De Filippo G et al. FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women. Eur J Endocrinol. 2010; 163(1):165-172. DOI: 10.1530/EJE-10-0043</mixed-citation><mixed-citation xml:lang="en">Rendina D, Gianfrancesco F, De Filippo G et al. FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women. Eur J Endocrinol. 2010; 163(1):165-172. DOI: 10.1530/EJE-10-0043</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Van Coillie E, Van Damme J, Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev. 1999; 10(1):61-86. DOI: 10.1016/s1359-6101(99)00005-2</mixed-citation><mixed-citation xml:lang="en">Van Coillie E, Van Damme J, Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev. 1999; 10(1):61-86. DOI: 10.1016/s1359-6101(99)00005-2</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Yu X, Graves DT. Fibroblasts, mononuclear phagocytes, and endothelial cells express monocyte chemoattractant protein-1 (MCP-1) in inflamed human gingiva. J Periodontol. 1995; 66(1):80-88. DOI: 10.1902/jop.1995.66.1.80</mixed-citation><mixed-citation xml:lang="en">Yu X, Graves DT. Fibroblasts, mononuclear phagocytes, and endothelial cells express monocyte chemoattractant protein-1 (MCP-1) in inflamed human gingiva. J Periodontol. 1995; 66(1):80-88. DOI: 10.1902/jop.1995.66.1.80</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-319. DOI: 10.1016/s0092-8674(00)80209-3</mixed-citation><mixed-citation xml:lang="en">Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-319. DOI: 10.1016/s0092-8674(00)80209-3</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP- 1 expression. Biochem Biophys Res Commun. 1999; 259(2):344-348. DOI: 10.1006/bbrc.1999.0796</mixed-citation><mixed-citation xml:lang="en">Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP- 1 expression. Biochem Biophys Res Commun. 1999; 259(2):344-348. DOI: 10.1006/bbrc.1999.0796</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Rollins BJ. Chemokines. Blood. 1997; 90:909– 928.</mixed-citation><mixed-citation xml:lang="en">Rollins BJ. Chemokines. Blood. 1997; 90:909– 928.</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Eraltan H, Cacina C, Kahraman OT et al. MCP-1 and CCR2 gene variants and the risk for osteoporosis and osteopenia. Genetic Testing and Molecular Biomarkers. 2012; 16(4):229–233. DOI: 10.1089/gtmb.2011.0216</mixed-citation><mixed-citation xml:lang="en">Eraltan H, Cacina C, Kahraman OT et al. MCP-1 and CCR2 gene variants and the risk for osteoporosis and osteopenia. Genetic Testing and Molecular Biomarkers. 2012; 16(4):229–233. DOI: 10.1089/gtmb.2011.0216</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Schlüter KD. PTH and PTHrP: Similar Structures but Different Functions. News Physiol Sci. 1999; 14:243- 249. DOI: 10.1152/physiologyonline.1999</mixed-citation><mixed-citation xml:lang="en">Schlüter KD. PTH and PTHrP: Similar Structures but Different Functions. News Physiol Sci. 1999; 14:243- 249. DOI: 10.1152/physiologyonline.1999</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Jans DA, Thomas RJ, Gillespie MT. Parathyroid hormone-related protein (PTHrP): a nucleocytoplasmic shuttling protein with distinct paracrine and intracrine roles. Vitam Horm. 2003; 66:345-384. DOI: 10.1016/s0083-6729(03)01010-0</mixed-citation><mixed-citation xml:lang="en">Jans DA, Thomas RJ, Gillespie MT. Parathyroid hormone-related protein (PTHrP): a nucleocytoplasmic shuttling protein with distinct paracrine and intracrine roles. Vitam Horm. 2003; 66:345-384. DOI: 10.1016/s0083-6729(03)01010-0</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Strewler GJ. The physiology of parathyroid hormone-related protein. N Engl J Med. 2000; 342(3):177- 185. DOI: 10.1056/NEJM200001203420306</mixed-citation><mixed-citation xml:lang="en">Strewler GJ. The physiology of parathyroid hormone-related protein. N Engl J Med. 2000; 342(3):177- 185. DOI: 10.1056/NEJM200001203420306</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Fiaschi-Taesch NM, Stewart AF. Minireview: parathyroid hormone-related protein as an intracrine factor- -trafficking mechanisms and functional consequences. Endocrinology. 2003; 144(2):407-411. DOI: 10.1210/en.2002-220818</mixed-citation><mixed-citation xml:lang="en">Fiaschi-Taesch NM, Stewart AF. Minireview: parathyroid hormone-related protein as an intracrine factor- -trafficking mechanisms and functional consequences. Endocrinology. 2003; 144(2):407-411. DOI: 10.1210/en.2002-220818</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Weiss S, Hennig T, Bock R et al. Impact of growth factors and PTHrP on early and late chondrogenic differentiation of human mesenchymal stem cells. J Cell Physiol. 2010; 223(1):84-93. DOI: 10.1002/jcp.22013</mixed-citation><mixed-citation xml:lang="en">Weiss S, Hennig T, Bock R et al. Impact of growth factors and PTHrP on early and late chondrogenic differentiation of human mesenchymal stem cells. J Cell Physiol. 2010; 223(1):84-93. DOI: 10.1002/jcp.22013</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Miao D, He B, Karaplis AC et al. Parathyroid hormone is essential for normal fetal bone formation. J Clin Invest. 2002; 109(9):1173-1182. DOI: 10.1172/JCI14817</mixed-citation><mixed-citation xml:lang="en">Miao D, He B, Karaplis AC et al. Parathyroid hormone is essential for normal fetal bone formation. J Clin Invest. 2002; 109(9):1173-1182. DOI: 10.1172/JCI14817</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">Boileau G, Tenenhouse HS, Desgroseillers L et al. Characterization of PHEX endopeptidase catalytic activity: identification of parathyroid-hormone-related peptide107-139 as a substrate and osteocalcin, PPi and phosphate as inhibitors. Biochem J. 2001; 355(Pt 3):707- 713. DOI: 10.1042/bj3550707</mixed-citation><mixed-citation xml:lang="en">Boileau G, Tenenhouse HS, Desgroseillers L et al. Characterization of PHEX endopeptidase catalytic activity: identification of parathyroid-hormone-related peptide107-139 as a substrate and osteocalcin, PPi and phosphate as inhibitors. Biochem J. 2001; 355(Pt 3):707- 713. DOI: 10.1042/bj3550707</mixed-citation></citation-alternatives></ref><ref id="cit105"><label>105</label><citation-alternatives><mixed-citation xml:lang="ru">Bisello A, Horwitz MJ, Stewart AF. Parathyroid hormone-related protein: an essential physiological regulator of adult bone mass. Endocrinology. 2004; 145(8):3551- 3553. DOI: 10.1210/en.2004-0509</mixed-citation><mixed-citation xml:lang="en">Bisello A, Horwitz MJ, Stewart AF. Parathyroid hormone-related protein: an essential physiological regulator of adult bone mass. Endocrinology. 2004; 145(8):3551- 3553. DOI: 10.1210/en.2004-0509</mixed-citation></citation-alternatives></ref><ref id="cit106"><label>106</label><citation-alternatives><mixed-citation xml:lang="ru">Horwitz MJ, Tedesco MB, Garcia-Ocaña A et al. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab. 2010; 95(3):1279- 1287. DOI: 10.1210/jc.2009-0233</mixed-citation><mixed-citation xml:lang="en">Horwitz MJ, Tedesco MB, Garcia-Ocaña A et al. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab. 2010; 95(3):1279- 1287. DOI: 10.1210/jc.2009-0233</mixed-citation></citation-alternatives></ref><ref id="cit107"><label>107</label><citation-alternatives><mixed-citation xml:lang="ru">Ahlström M, Pekkinen M, Lamberg-Allardt C. Dexamethasone downregulates the expression of parathyroid hormone-related protein (PTHrP) in mesenchymal stem cells. Steroids. 2009; 74(2):277-282. DOI: 10.1016/j.steroids.2008.12.002</mixed-citation><mixed-citation xml:lang="en">Ahlström M, Pekkinen M, Lamberg-Allardt C. Dexamethasone downregulates the expression of parathyroid hormone-related protein (PTHrP) in mesenchymal stem cells. Steroids. 2009; 74(2):277-282. DOI: 10.1016/j.steroids.2008.12.002</mixed-citation></citation-alternatives></ref><ref id="cit108"><label>108</label><citation-alternatives><mixed-citation xml:lang="ru">Scillitani A, Jang C, Wong BY et al. A functional polymorphism in the PTHR1 promoter region is associated with adult height and BMD measured at the femoral neck in a large cohort of young caucasian women. Hum Genet. 2006; 119(4):416-421. DOI: 10.1007/s00439-006-0155-8</mixed-citation><mixed-citation xml:lang="en">Scillitani A, Jang C, Wong BY et al. A functional polymorphism in the PTHR1 promoter region is associated with adult height and BMD measured at the femoral neck in a large cohort of young caucasian women. Hum Genet. 2006; 119(4):416-421. DOI: 10.1007/s00439-006-0155-8</mixed-citation></citation-alternatives></ref><ref id="cit109"><label>109</label><citation-alternatives><mixed-citation xml:lang="ru">Lee HJ, Kim SY, Kim GS et al. Fracture, bone mineral density, and the effects of calcitonin receptor gene in postmenopausal Koreans. Osteoporos Int. 2010;21(8):1351- 1360. DOI: 10.1007/s00198-009-1106-8</mixed-citation><mixed-citation xml:lang="en">Lee HJ, Kim SY, Kim GS et al. Fracture, bone mineral density, and the effects of calcitonin receptor gene in postmenopausal Koreans. Osteoporos Int. 2010;21(8):1351- 1360. DOI: 10.1007/s00198-009-1106-8</mixed-citation></citation-alternatives></ref><ref id="cit110"><label>110</label><citation-alternatives><mixed-citation xml:lang="ru">Aguiar-Oliveira MH, Cardoso-Filho MA, Pereira RM et al. Older individuals heterozygous for a growth hormone-releasing hormone receptor gene mutation are shorter than normal subjects. J Hum Genet. 2015; 60(6):335- 338. DOI: 10.1038/jhg.2015.25</mixed-citation><mixed-citation xml:lang="en">Aguiar-Oliveira MH, Cardoso-Filho MA, Pereira RM et al. Older individuals heterozygous for a growth hormone-releasing hormone receptor gene mutation are shorter than normal subjects. J Hum Genet. 2015; 60(6):335- 338. DOI: 10.1038/jhg.2015.25</mixed-citation></citation-alternatives></ref><ref id="cit111"><label>111</label><citation-alternatives><mixed-citation xml:lang="ru">Faivre E, Gault VA, Thorens B et al. Glucosedependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis. J Neurophysiol. 2011; 105(4):1574-1580. DOI: 10.1152/jn.00866.2010</mixed-citation><mixed-citation xml:lang="en">Faivre E, Gault VA, Thorens B et al. Glucosedependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis. J Neurophysiol. 2011; 105(4):1574-1580. DOI: 10.1152/jn.00866.2010</mixed-citation></citation-alternatives></ref><ref id="cit112"><label>112</label><citation-alternatives><mixed-citation xml:lang="ru">Torekov SS, Harsløf T, Rejnmark L et al. A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk. J Clin Endocrinol Metab. 2014; 99(4):E729- 733. DOI: 10.1210/jc.2013-3766</mixed-citation><mixed-citation xml:lang="en">Torekov SS, Harsløf T, Rejnmark L et al. A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk. J Clin Endocrinol Metab. 2014; 99(4):E729- 733. DOI: 10.1210/jc.2013-3766</mixed-citation></citation-alternatives></ref><ref id="cit113"><label>113</label><citation-alternatives><mixed-citation xml:lang="ru">Mórocz M, Czibula A, Grózer ZB et al. Association study of BMP4, IL6, Leptin, MMP3, and MTNR1B gene promoter polymorphisms and adolescent idiopathic scoliosis. Spine (Phila Pa 1976). 2011; 36(2):E123-130. DOI: 10.1097/BRS.0b013e318a511b0e</mixed-citation><mixed-citation xml:lang="en">Mórocz M, Czibula A, Grózer ZB et al. Association study of BMP4, IL6, Leptin, MMP3, and MTNR1B gene promoter polymorphisms and adolescent idiopathic scoliosis. Spine (Phila Pa 1976). 2011; 36(2):E123-130. DOI: 10.1097/BRS.0b013e318a511b0e</mixed-citation></citation-alternatives></ref><ref id="cit114"><label>114</label><citation-alternatives><mixed-citation xml:lang="ru">Kalinkovich A, Livshits G. Biased and allosteric modulation of bone cell-expressing G protein-coupled receptors as a novel approach to osteoporosis therapy. Pharmacol Res. 2021; 171:105794. DOI: 10.1016/j.phrs.2021.105794</mixed-citation><mixed-citation xml:lang="en">Kalinkovich A, Livshits G. Biased and allosteric modulation of bone cell-expressing G protein-coupled receptors as a novel approach to osteoporosis therapy. Pharmacol Res. 2021; 171:105794. DOI: 10.1016/j.phrs.2021.105794</mixed-citation></citation-alternatives></ref><ref id="cit115"><label>115</label><citation-alternatives><mixed-citation xml:lang="ru">Ricci F, Vacchetti M, Brusa C et al. New pharmacotherapies for genetic neuromuscular disorders: opportunities and challenges. Expert Rev Clin Pharmacol. 2019; 12(8):757-770. DOI: 10.1080/17512433.2019.1634543</mixed-citation><mixed-citation xml:lang="en">Ricci F, Vacchetti M, Brusa C et al. New pharmacotherapies for genetic neuromuscular disorders: opportunities and challenges. Expert Rev Clin Pharmacol. 2019; 12(8):757-770. DOI: 10.1080/17512433.2019.1634543</mixed-citation></citation-alternatives></ref><ref id="cit116"><label>116</label><citation-alternatives><mixed-citation xml:lang="ru">Bannuru RR, Osani MC, Vaysbrot EE et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019; 27(11):1578-1589. DOI: 10.1016/j.joca.2019.06.011</mixed-citation><mixed-citation xml:lang="en">Bannuru RR, Osani MC, Vaysbrot EE et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019; 27(11):1578-1589. DOI: 10.1016/j.joca.2019.06.011</mixed-citation></citation-alternatives></ref><ref id="cit117"><label>117</label><citation-alternatives><mixed-citation xml:lang="ru">Thysen S, Luyten FP, Lories RJ. Targets, models and challenges in osteoarthritis research. Dis Model Mech. 2015; 8(1):17-30. DOI: 10.1242/dmm.016881</mixed-citation><mixed-citation xml:lang="en">Thysen S, Luyten FP, Lories RJ. Targets, models and challenges in osteoarthritis research. Dis Model Mech. 2015; 8(1):17-30. DOI: 10.1242/dmm.016881</mixed-citation></citation-alternatives></ref><ref id="cit118"><label>118</label><citation-alternatives><mixed-citation xml:lang="ru">Singh VK, Kalsan M, Kumar N et al. Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery. Front Cell Dev Biol. 2015; 3:2. DOI: 10.3389/fcell.2015.00002</mixed-citation><mixed-citation xml:lang="en">Singh VK, Kalsan M, Kumar N et al. Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery. Front Cell Dev Biol. 2015; 3:2. DOI: 10.3389/fcell.2015.00002</mixed-citation></citation-alternatives></ref><ref id="cit119"><label>119</label><citation-alternatives><mixed-citation xml:lang="ru">Desnuelle C, Dib M, Garrel C et al. A doubleblind, placebo-controlled randomized clinical trial of alphatocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 2(1):9-18. DOI: 10.1080/146608201300079364</mixed-citation><mixed-citation xml:lang="en">Desnuelle C, Dib M, Garrel C et al. A doubleblind, placebo-controlled randomized clinical trial of alphatocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 2(1):9-18. DOI: 10.1080/146608201300079364</mixed-citation></citation-alternatives></ref><ref id="cit120"><label>120</label><citation-alternatives><mixed-citation xml:lang="ru">Shefner JM, Cudkowicz ME, Schoenfeld D et al. A clinical trial of creatine in ALS. Neurology. 2004; 63(9):1656-1661. DOI: 10.1212/01.wnl.0000142992.81995.f0</mixed-citation><mixed-citation xml:lang="en">Shefner JM, Cudkowicz ME, Schoenfeld D et al. A clinical trial of creatine in ALS. Neurology. 2004; 63(9):1656-1661. DOI: 10.1212/01.wnl.0000142992.81995.f0</mixed-citation></citation-alternatives></ref><ref id="cit121"><label>121</label><citation-alternatives><mixed-citation xml:lang="ru">Li WJ, Jiao H, Walczak BE. Emerging opportunities for induced pluripotent stem cells in orthopaedics. J Orthop Translat. 2019; 17:73-81. DOI: 10.1016/j.jot.2019.03.001</mixed-citation><mixed-citation xml:lang="en">Li WJ, Jiao H, Walczak BE. Emerging opportunities for induced pluripotent stem cells in orthopaedics. J Orthop Translat. 2019; 17:73-81. DOI: 10.1016/j.jot.2019.03.001</mixed-citation></citation-alternatives></ref><ref id="cit122"><label>122</label><citation-alternatives><mixed-citation xml:lang="ru">Park IH, Arora N, Huo H et al. Disease-specific induced pluripotent stem cells. Cell. 2008; 134(5):877-886. DOI: 10.1016/j.cell.2008.07.041</mixed-citation><mixed-citation xml:lang="en">Park IH, Arora N, Huo H et al. Disease-specific induced pluripotent stem cells. Cell. 2008; 134(5):877-886. DOI: 10.1016/j.cell.2008.07.041</mixed-citation></citation-alternatives></ref><ref id="cit123"><label>123</label><citation-alternatives><mixed-citation xml:lang="ru">Csobonyeiova M, Polak S, Zamborsky R et al. iPS cell technologies and their prospect for bone regeneration and disease modeling: A mini review. J Adv Res. 2017; 8(4):321-327. DOI: 10.1016/j.jare.2017.02.004</mixed-citation><mixed-citation xml:lang="en">Csobonyeiova M, Polak S, Zamborsky R et al. iPS cell technologies and their prospect for bone regeneration and disease modeling: A mini review. J Adv Res. 2017; 8(4):321-327. DOI: 10.1016/j.jare.2017.02.004</mixed-citation></citation-alternatives></ref><ref id="cit124"><label>124</label><citation-alternatives><mixed-citation xml:lang="ru">Kao CL, Tai LK, Chiou SH et al. Resveratrol promotes osteogenic differentiation and protects against dexamethasone damage in murine induced pluripotent stem cells. Stem Cells Dev. 2010; 19(2):247-258. DOI: 10.1089/scd.2009.0186</mixed-citation><mixed-citation xml:lang="en">Kao CL, Tai LK, Chiou SH et al. Resveratrol promotes osteogenic differentiation and protects against dexamethasone damage in murine induced pluripotent stem cells. Stem Cells Dev. 2010; 19(2):247-258. DOI: 10.1089/scd.2009.0186</mixed-citation></citation-alternatives></ref><ref id="cit125"><label>125</label><citation-alternatives><mixed-citation xml:lang="ru">Ardeshirylajimi A, Soleimani M. Enhanced growth and osteogenic di_erentiation of induced pluripotent stem cells by extremely low-frequency electromagnetic field. Cell Mol Biol. 2015; 61: 36–41.</mixed-citation><mixed-citation xml:lang="en">Ardeshirylajimi A, Soleimani M. Enhanced growth and osteogenic di_erentiation of induced pluripotent stem cells by extremely low-frequency electromagnetic field. Cell Mol Biol. 2015; 61: 36–41.</mixed-citation></citation-alternatives></ref><ref id="cit126"><label>126</label><citation-alternatives><mixed-citation xml:lang="ru">Sanjurjo-Rodríguez C, Castro-Viñuelas R, Piñeiro-Ramil M et al. Versatility of Induced Pluripotent Stem Cells (iPSCs) for Improving the Knowledge on Musculoskeletal Diseases. Int J Mol Sci. 2020; 21(17):6124. DOI: 10.3390/ijms21176124</mixed-citation><mixed-citation xml:lang="en">Sanjurjo-Rodríguez C, Castro-Viñuelas R, Piñeiro-Ramil M et al. Versatility of Induced Pluripotent Stem Cells (iPSCs) for Improving the Knowledge on Musculoskeletal Diseases. Int J Mol Sci. 2020; 21(17):6124. DOI: 10.3390/ijms21176124</mixed-citation></citation-alternatives></ref><ref id="cit127"><label>127</label><citation-alternatives><mixed-citation xml:lang="ru">Ou M, Li C, Tang D et al. Genotyping, generation and proteomic profiling of the first human autosomal dominant osteopetrosis type II-specific induced pluripotent stem cells. Stem Cell Res Ther. 2019; 10(1):251. DOI: 10.1186/s13287-019-1369-8</mixed-citation><mixed-citation xml:lang="en">Ou M, Li C, Tang D et al. Genotyping, generation and proteomic profiling of the first human autosomal dominant osteopetrosis type II-specific induced pluripotent stem cells. Stem Cell Res Ther. 2019; 10(1):251. DOI: 10.1186/s13287-019-1369-8</mixed-citation></citation-alternatives></ref><ref id="cit128"><label>128</label><citation-alternatives><mixed-citation xml:lang="ru">Kawai S, Yoshitomi H, Sunaga J et al. In vitro bone-like nodules generated from patient-derived iPSCs recapitulate pathological bone phenotypes. Nat Biomed Eng. 2019; 3(7):558-570. DOI: 10.1038/s41551-019-0410-7</mixed-citation><mixed-citation xml:lang="en">Kawai S, Yoshitomi H, Sunaga J et al. In vitro bone-like nodules generated from patient-derived iPSCs recapitulate pathological bone phenotypes. Nat Biomed Eng. 2019; 3(7):558-570. DOI: 10.1038/s41551-019-0410-7</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
